SALL1 Protein

📖 Wiki Page

protein1203 wordssynced 2026-04-02

SALL1 Protein (Sal-like protein 1)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8d8c8; text-align:center; font-size:1.1em;">Sal-like protein 1 (SALL1)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Sal-like protein 1</td></tr>
<tr><td><strong>Gene</strong></td><td><a href="/genes/sall1">SALL1</a></td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/Q9BX63" target="_blank">Q9BX63</a></td></tr>
<tr><td><strong>PDB Structures</strong></td><td>No PDB structure available</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>144,000 Da</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SALL family, C2H2 zinc finger family</td></tr>
<tr><td><strong>Protein Length</strong></td><td>1,322 amino acids</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
</div>

Overview

...

SALL1 Protein (Sal-like protein 1)

Overview

SALL1 (Sal-like protein 1) is a member of the SALL family of C2H2 zinc-finger transcription factors that plays a critical role in the development and maintenance of microglia, the resident immune cells of the central nervous system. First characterized for its role in organ development, SALL1 has emerged as a key molecular marker of homeostatic microglia and a regulator of the disease-associated microglia (DAM) phenotype in neurodegenerative conditions including Alzheimer's disease (AD) and Parkinson's disease (PD)[@tchieu2019].

The protein is predominantly expressed in microglia within the brain, where it serves as a master regulator of microglial identity, controlling the expression of genes essential for microglial survival, function, and transformation into disease-associated states. Loss of SALL1 expression is considered a hallmark of microglial dysregulation in neurodegenerative disease[@zhao2022].

Molecular Structure

SALL1 is a large transcription factor comprising 1,322 amino acids with the following structural features:

Domain Architecture

C2H2 Zinc Finger Domains: SALL1 contains multiple C2H2 zinc finger motifs (approximately 10 zinc fingers) that mediate DNA binding to specific promoter and enhancer regions[@schneeberger2019]. These zinc fingers recognize the consensus sequence (GGAA/T) and enable targeting of gene regulatory elements.
Transcription Repressor Domain: The N-terminal region contains a transcriptional repressor domain that recruits chromatin-modifying complexes, including histone deacetylases (HDACs) and the Nucleosome Remodeling and Deacetylase (NuRD) complex.
Dimerization Domain: SALL1 can form homodimers through its C-terminal region, enabling cooperative DNA binding and transcriptional regulation.

Post-Translational Modifications

Phosphorylation: SALL1 activity is modulated by phosphorylation events that affect its DNA-binding affinity and protein-protein interactions.
Sumoylation: Sumoylation of SALL1 influences its transcriptional repressor function and subnuclear localization.

Normal Physiological Function

Microglial Development

During embryonic development, SALL1 is expressed in yolk sac-derived microglial precursors and is essential for the specification of the microglial lineage[@butovsky2014]. It controls the transcriptional program that distinguishes microglia from other tissue macrophages, including expression of genes involved in:

Immune surveillance
Synaptic pruning
Brain homeostasis maintenance

Adult Brain Function

In the adult brain, SALL1+ microglia represent the predominant population and are characterized by[@sink2020]:

High expression of microglial signature genes (CX3CR1, P2RY12, TMEM119)
Enhanced phagocytic capacity
Anti-inflammatory phenotype
Metabolic fitness for brain homeostasis

SALL1 maintains microglial identity by repressing genes associated with the DAM or neurodegenerative phenotype. It does this through direct binding to promoters of pro-inflammatory genes and by recruiting chromatin modifiers that maintain a closed chromatin state at these loci[@nakamura2021].

Role in Neurodegenerative Diseases

Alzheimer's Disease

SALL1 plays a complex and context-dependent role in Alzheimer's disease pathogenesis:

Disease-Associated Microglia Transition: During AD progression, microglia undergo a transformation from a homeostatic (SALL1+) state to a disease-associated (SALL1-low/null) state. This transition is characterized by[@krasemann2017]:

Downregulation of SALL1 and other homeostatic genes
Upregulation of TREM2, APOE, and pro-inflammatory genes
Acquisition of a phagocytic but potentially harmful phenotype

Protective vs. Pathogenic Effects: The loss of SALL1 in AD microglia may be both protective (reducing excessive immune activation) and pathogenic (impairing synaptic maintenance and increasing neuroinflammation)[@zhao2022]. Studies show that:

SALL1 deficiency leads to increased production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6)

Loss of SALL1 impairs microglial phagocytosis of amyloid-beta plaques

Restoring SALL1 in aged microglia improves cognitive function in AD mouse models[@holland2023]

Therapeutic Implications: Targeting SALL1 modulation represents a novel therapeutic approach for AD. Strategies under investigation include[@fan2022]:

SALL1 expression restoration using viral vectors
Epigenetic therapies to reactivate SALL1 transcription
Small molecules that stabilize SALL1 protein

Parkinson's Disease

In Parkinson's disease, SALL1+ microglia are similarly affected:

SALL1 expression is reduced in substantia nigra microglia
Loss of SALL1 correlates with increased neuroinflammation in PD models
SALL1 deficiency exacerbates dopaminergic neuron loss through enhanced microglial activation

Other Neurodegenerative Conditions

SALL1 dysregulation has been implicated in:

Amyotrophic Lateral Sclerosis (ALS): SALL1+ microglia show reduced coverage of motor neurons
Multiple Sclerosis: SALL1 expression inversely correlates with lesion activity
Frontotemporal Dementia: Microglial SALL1 loss associated with TDP-43 pathology

Signaling Pathways and Interactions

TREM2-APOE-SALL1 Axis

SALL1 interacts closely with the TREM2-APOE signaling pathway, a critical regulator of microglial function[@wang2023]:

ApoE/TREM2 signaling --> SALL1 expression --> Microglial phenotype
↓ ↓
Lipid metabolism Chromatin remodeling
↓ ↓
DAM phenotype Inflammatory gene repression

This axis governs the metabolic and functional transformation of microglia in neurodegenerative conditions.

TGF-beta Signaling

TGF-beta signaling is a key upstream regulator of SALL1 expression. Microglial SALL1 expression is induced by TGF-beta and maintained through the TGF-beta receptor signaling cascade[@butovsky2014]. Disruption of TGF-beta signaling leads to SALL1 downregulation and microglial dysfunction.

Chromatin Remodeling Complexes

SALL1 recruits multiple chromatin remodeling complexes:

NuRD Complex: Mediates histone deacetylation and nucleosome remodeling at target genes
Polycomb Repressive Complex 2 (PRC2): Deposits H3K27me3 marks for gene silencing
SWI/SNF Complex: Facilitates ATP-dependent chromatin remodeling

Therapeutic Targeting

Current Strategies

Gene Therapy: Viral delivery of SALL1 to the brain to restore microglial homeostasis

Epigenetic Drugs: HDAC inhibitors or DNA methyltransferase inhibitors to reactivate SALL1 expression

Small Molecule Stabilizers: Compounds that stabilize SALL1 protein and prevent its degradation

Challenges

Blood-brain barrier delivery to microglia
Achieving appropriate SALL1 expression levels (both insufficient and excessive can be problematic)
Cell-type specific targeting to avoid off-target effects

Preclinical Progress

Recent studies have shown promise:

AAV-mediated SALL1 delivery reduces neuroinflammation in AD mouse models[@holland2023]
SALL1 overexpression improves synaptic function and cognitive performance
Combined SALL1 and TREM2 modulation shows synergistic benefits[@wang2023]

Expression Patterns

Brain Region Distribution

SALL1+ microglia are distributed throughout the brain with highest density in:

Hippocampus (particularly CA1 and dentate gyrus)
Cerebral cortex (layer 2/3)
Cerebellum (Purkinje cell layer)
Substantia nigra (pars reticulata)

SALL1 expression in microglia declines with age[@sink2020]:

Young brain: >95% of microglia are SALL1+
Aged brain: SALL1+ microglia reduced to ~70%
This age-related decline may contribute to increased neuroinflammation and cognitive decline

Disease-Associated Changes

In neurodegenerative diseases, SALL1 expression shows:

Early stage AD: Moderate reduction (SALL1+ ~60-70%)
Advanced AD: Severe reduction (SALL1+ <30%)
Similar patterns observed in PD, ALS, and FTD

Key Research Findings

| Year | Finding | Reference |
|------|---------|-----------|
| 2019 | SALL1 defines microglial activation state | [@tchieu2019] |
| 2022 | SALL1 controls inflammatory response in AD | [@zhao2022] |
| 2022 | Spatial profiling of SALL1+ microglia in AD | [@masuda2022] |
| 2023 | Restoring SALL1 improves cognitive function | [@holland2023] |
| 2023 | SALL1-TREM2 crosstalk in microglial activation | [@wang2023] |
| 2024 | Epigenetic remodeling of SALL1 in DAM | [@yoshikawa2024] |

SALL1 Protein

SALL1 Protein (Sal-like protein 1)

Overview

SALL1 Protein (Sal-like protein 1)

Overview

Molecular Structure

Domain Architecture

Post-Translational Modifications

Normal Physiological Function

Microglial Development

Adult Brain Function

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Signaling Pathways and Interactions

TREM2-APOE-SALL1 Axis

TGF-beta Signaling

Chromatin Remodeling Complexes

Therapeutic Targeting

Current Strategies

Challenges

Preclinical Progress

Expression Patterns

Brain Region Distribution

Age-Related Changes

Disease-Associated Changes

Key Research Findings

See Also